Share-based Payment Arrangement, Expense of Edgewise Therapeutics, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Edgewise Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Edgewise Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $8,085,000, a 18% increase year-over-year.
  • Edgewise Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $32,613,000, a 47% increase year-over-year.
  • Edgewise Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $24,711,000, a 41% increase from 2023.
  • Edgewise Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $17,560,000, a 61% increase from 2022.
  • Edgewise Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,924,000, a 148% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Edgewise Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $32,613,000 $8,085,000 +$1,205,000 +18% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $31,408,000 $7,733,000 +$2,509,000 +48% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $28,899,000 $9,059,000 +$4,188,000 +86% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $24,711,000 $7,736,000 +$2,583,000 +50% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $22,128,000 $6,880,000 +$2,321,000 +51% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $19,807,000 $5,224,000 +$1,213,000 +30% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $18,594,000 $4,871,000 +$1,034,000 +27% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $17,560,000 $5,153,000 +$1,417,000 +38% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $16,143,000 $4,559,000 +$1,386,000 +44% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $14,757,000 $4,011,000 +$1,974,000 +97% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $12,783,000 $3,837,000 +$1,859,000 +94% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $10,924,000 $3,736,000 +$1,863,000 +99% 01 Oct 2022 31 Dec 2022 10-K 22 Feb 2024 2023 FY
Q3 2022 $9,061,000 $3,173,000 +$1,625,000 +105% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $7,436,000 $2,037,000 +$1,350,000 +197% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $6,086,000 $1,978,000 +$1,682,000 +568% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $4,404,000 $1,873,000 +$1,683,000 +886% 01 Oct 2021 31 Dec 2021 10-K 23 Feb 2023 2022 FY
Q3 2021 $2,721,000 $1,548,000 +$1,478,000 +2111% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $1,243,000 $687,000 +$638,000 +1302% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $605,000 $296,000 +$251,000 +558% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $354,000 $190,000 01 Oct 2020 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q3 2020 $70,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $49,000 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $45,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1

Edgewise Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $24,711,000 +$7,151,000 +41% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $17,560,000 +$6,636,000 +61% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $10,924,000 +$6,520,000 +148% 01 Jan 2022 31 Dec 2022 10-K 22 Feb 2024 2023 FY
2021 $4,404,000 +$4,050,000 +1144% 01 Jan 2021 31 Dec 2021 10-K 23 Feb 2023 2022 FY
2020 $354,000 01 Jan 2020 31 Dec 2020 10-K 24 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.